In the two DCM patients with the CC genotype, empagliflozin increased cardiac TLR9 protein abundance, while in the DCM patient with the TT genotype, empagliflozin treatment did not increase the TLR9 abundance (Figure 6H). Here, TLR9 is linked to familial dilated cardiomyopathy.